Skip to main
XRAY
XRAY logo

DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target

DENTSPLY SIRONA (XRAY) Analyst Ratings

Based on 24 analyst ratings
Hold
Strong Buy 17%
Buy 25%
Hold 54%
Sell 4%
Strong Sell 0%

Bulls say

Dentsply Sirona's sales in Europe experienced a reported growth of 2.8% and an organic growth of 1.8%, indicating a steady demand for its dental products in a significant market. Furthermore, the company's subsidiary, Wellspect Healthcare, generated $81 million in revenue, surpassing consensus estimates and achieving an organic growth rate of 6.7% in the fourth quarter of 2024, highlighting strong performance and product innovation. Overall, there are anticipations of accelerating revenue growth into the mid-single digits in the coming years, driven by factors such as market share gains in clear aligners, recovery in the implants sector, and ongoing margin improvements.

Bears say

Dentsply Sirona's financial outlook is negatively impacted by a significant shortfall in profitability, with an adjusted EPS of $0.26, falling well below expectations of $0.43. The company's connected technology solutions segment experienced an 8.3% decline in revenue, indicating ongoing challenges, while the Byte shutdown alone accounted for a $62 million loss in revenue and a $0.24 reduction in adjusted EPS. Additionally, increasing operating expenses and a gross margin contraction of 240 basis points year-over-year further exacerbate concerns about the company's financial stability and future growth prospects.

DENTSPLY SIRONA (XRAY) has been analyzed by 24 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 25% recommend Buy, 54% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DENTSPLY SIRONA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DENTSPLY SIRONA (XRAY) Forecast

Analysts have given DENTSPLY SIRONA (XRAY) a Hold based on their latest research and market trends.

According to 24 analysts, DENTSPLY SIRONA (XRAY) has a Hold consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DENTSPLY SIRONA (XRAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.